The CCL20 and CCR6 axis in psoriasis
- PMID: 31692008
- DOI: 10.1111/sji.12846
The CCL20 and CCR6 axis in psoriasis
Abstract
Psoriasis is a TNF-α/IL-23/IL-17A-mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL-17A-producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL-17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL-17A-rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.
Keywords: CCL20; CCR6; Koebner phenomenon; Th17; psoriasis.
© 2019 The Scandinavian Foundation for Immunology.
Similar articles
-
Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment.Exp Dermatol. 2011 Oct;20(10):855-7. doi: 10.1111/j.1600-0625.2011.01343.x. Epub 2011 Aug 8. Exp Dermatol. 2011. PMID: 21824198
-
Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model.Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12460-12465. doi: 10.1073/pnas.1704958114. Epub 2017 Nov 6. Proc Natl Acad Sci U S A. 2017. PMID: 29109267 Free PMC article.
-
Development of psoriasis by continuous neutrophil infiltration into the epidermis.Exp Dermatol. 2018 Oct;27(10):1084-1091. doi: 10.1111/exd.13746. Epub 2018 Aug 14. Exp Dermatol. 2018. PMID: 30019426 Review.
-
Anti-psoriasis effect of 18β-glycyrrhetinic acid by breaking CCL20/CCR6 axis through its vital active group targeting GUSB/ATF2 signaling.Phytomedicine. 2024 Jun;128:155524. doi: 10.1016/j.phymed.2024.155524. Epub 2024 Mar 16. Phytomedicine. 2024. PMID: 38552435
-
Interleukin-17A and Keratinocytes in Psoriasis.Int J Mol Sci. 2020 Feb 13;21(4):1275. doi: 10.3390/ijms21041275. Int J Mol Sci. 2020. PMID: 32070069 Free PMC article. Review.
Cited by
-
Bath Psoralen Plus UVA Therapy Suppresses Keratinocyte-Derived Chemokines in Pathogenetically Relevant Cells.JID Innov. 2021 May 24;1(3):100027. doi: 10.1016/j.xjidi.2021.100027. eCollection 2021 Sep. JID Innov. 2021. PMID: 34909726 Free PMC article.
-
Progress of CCL20-CCR6 in the airways: a promising new therapeutic target.J Inflamm (Lond). 2024 Dec 27;21(1):54. doi: 10.1186/s12950-024-00427-5. J Inflamm (Lond). 2024. PMID: 39731176 Free PMC article. Review.
-
Gamma Delta T Cells and Their Pathogenic Role in Psoriasis.Front Immunol. 2021 Feb 25;12:627139. doi: 10.3389/fimmu.2021.627139. eCollection 2021. Front Immunol. 2021. PMID: 33732249 Free PMC article. Review.
-
Identification of hub genes for psoriasis and thyroid cancer using bioinformatics analysis.Discov Oncol. 2025 Aug 2;16(1):1460. doi: 10.1007/s12672-025-03305-5. Discov Oncol. 2025. PMID: 40753287 Free PMC article.
-
Severe Scalp Psoriasis Microbiome Has Increased Biodiversity and Relative Abundance of Pseudomonas Compared to Mild Scalp Psoriasis.J Clin Med. 2022 Nov 30;11(23):7133. doi: 10.3390/jcm11237133. J Clin Med. 2022. PMID: 36498707 Free PMC article.
References
REFERENCES
-
- Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983-994.
-
- Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5-13.
-
- Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45:264-272.
-
- Ito T, Takahashi H, Kawada A, Iizuka H, Nakagawa H. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol. 2018;45:293-301.
-
- Ichiyama S, Ito M, Funasaka Y, et al. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities. J Dermatol. 2018;45:727-731.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical